{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T16:26:03Z","timestamp":1781108763746,"version":"3.54.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.jhep.2011.12.007","type":"journal-article","created":{"date-parts":[[2012,1,13]],"date-time":"2012-01-13T16:04:47Z","timestamp":1326470687000},"page":"1006-1011","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":145,"title":["Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a"],"prefix":"10.1016","volume":"56","author":[{"given":"Vincent","family":"Rijckborst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina E.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ferenci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizia R.","family":"Brunetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fehmi","family":"Tabak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilmaz","family":"Cakaloglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Galeota","family":"Lanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Iannacone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Massetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Regep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry L.A.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Lampertico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2011.12.007_b0005","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1517\/13543784.16.6.777","article-title":"Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients","volume":"16","author":"Hadziyannis","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jhep.2011.12.007_b0010","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy","volume":"49","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2011.12.007_b0015","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.gastro.2010.10.011","article-title":"Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B","volume":"140","author":"Heathcote","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2011.12.007_b0020","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1056\/NEJMoa042957","article-title":"Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B","volume":"352","author":"Hadziyannis","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2011.12.007_b0025","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S0168-8278(00)80076-8","article-title":"Long-term follow-up of patients with anti-HBe\/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine","volume":"32","author":"Santantonio","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2011.12.007_b0030","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jhep.2008.10.017","article-title":"Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy","volume":"50","author":"Shouval","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2011.12.007_b0035","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jhep.2008.10.001","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B","volume":"50","author":"European Association For The Study Of The Liver","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2011.12.007_b0040","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12072-008-9080-3","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update","volume":"2","author":"Liaw","year":"2008","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2011.12.007_b0045","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2011.12.007_b0050","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jhep.2008.01.011","article-title":"Hepatitis B: reflections on the current approach to antiviral therapy","volume":"48","author":"Zoulim","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2011.12.007_b0055","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/gut.2005.089722","article-title":"Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B","volume":"56","author":"Bonino","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2011.12.007_b0060","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/hep.22760","article-title":"Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B","volume":"49","author":"Brunetto","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2011.12.007_b0065","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1111\/j.1572-0241.2007.01449.x","article-title":"A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B","volume":"102","author":"Gish","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2011.12.007_b0070","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.22744","article-title":"Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients","volume":"49","author":"Moucari","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2011.12.007_b0075","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/hep.23722","article-title":"Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels","volume":"52","author":"Rijckborst","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2011.12.007_b0080","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2011.12.007_b0085","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/S0168-8278(10)60100-6","article-title":"Extended (2 years) treatment with peginterferon alfa-2a [40kD] improves sustained response rates in genotype D patients with HBeAg negative chronic hepatitis B","volume":"52","author":"Lampertico","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2011.12.007_b0090","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1038\/ajg.2010.186","article-title":"A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B","volume":"105","author":"Rijckborst","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"2169\u20132179","key":"10.1016\/j.jhep.2011.12.007_b0095","first-page":"e2161","article-title":"Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a","volume":"136","author":"Marcellin","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2011.12.007_b0100","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11901-010-0041-7","article-title":"Pros and cons of peginterferon versus nucleos(t)ide analogues for treatment of chronic hepatitis B","volume":"9","author":"Sonneveld","year":"2010","journal-title":"Curr Hepat Rep"},{"key":"10.1016\/j.jhep.2011.12.007_b0105","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3851\/IMP1458","article-title":"Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a","volume":"14","author":"Moucari","year":"2009","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2011.12.007_b0110","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1053\/jhep.2003.50148","article-title":"Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy","volume":"37","author":"Lampertico","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2011.12.007_b0115","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1053\/jhep.2001.27834","article-title":"Hepatitis B e antigen-negative chronic hepatitis B","volume":"34","author":"Hadziyannis","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2011.12.007_b0120","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/hep.21723","article-title":"Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis","volume":"46","author":"Buster","year":"2007","journal-title":"Hepatology"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827812000451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827812000451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:33:15Z","timestamp":1759174395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827812000451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0168827812000451"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2011.12.007","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2011.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}